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Objective/background: Epstein Barr Virus (EBV) DNA load is increasingly being used as a non-
invasive biomarker for detecting EBV association in lymphomas. Since there is a need of data
from India, we undertook to prospectively evaluate plasma EBV DNA load as a marker of EBV
association in newly diagnosed adult-onset Hodgkin lymphoma (HL).
Methods: EBV DNA was quantified using real-time polymerase chain reaction. In a subset of
patients, an assay was validated qualitatively with EBV latent membrane protein-1 (LMP1)
immunohistochemistry (IHC). Wherever possible, follow-up plasma samples post three cycles
of chemotherapy were obtained.
Results: Over a period of 10 months, 33 newly diagnosed adult-onset HL were enrolled in the
study. Pretherapy plasma EBV DNA was detectable in 49% (16/33) patients (viral loads range,
1.0–51.2  103 copies/mL) and undetectable in 30 voluntary blood donors. LMP1 IHC was pos-
itive in 56% of cases tested (14/25). Sensitivity and specificity of plasma EBV DNA with respect
to LMP1 IHC were 86% and 100%, respectively. Of the eight patients in whom follow-up plasma
was available, in five EBV baseline-positive patients EBV load reverted to negative
postchemotherapy and corroborated with clinical remission.Marigowda
acticing in
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possibly monitoring the response to therapy in EBV-related HL especially in our country where
EBV association of HL is higher than in developed nations.
 2015 King Faisal Specialist Hospital & Research Centre. Published by Elsevier Ltd. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).Introduction
Epstein Barr Virus (EBV) is associated with a variety of
human malignancies: Burkitt’s lymphoma, lymphomas asso-
ciated with immunosuppression, nonHodgkin lymphomas,
Hodgkin lymphoma (HL), and nasopharyngeal carcinoma
[1,2]. Seroepidemiologic studies indicate that EBV infects
>95% of the human population by adulthood and is main-
tained latently in a small fraction of memory B cells
[1–3]. While EBV DNA can be detected in the serum or
plasma of most patients with EBV-associated malignancies,
it remains undetectable in healthy individuals even though
they are latently infected [4–6]. Hence, a serum/plasma
EBV DNA detection assay can be used as a marker of EBV-
associated malignancies. In recent years, plasma EBV-DNA
assays are increasingly being used as a noninvasive biomar-
ker for EBV-association in lymphomas [5,7–14].
In order to validate its utility in determining EBV associa-
tion, there is a need for studies from different geographical
regions. In overcrowded living and unsanitary conditions of
developing countries like India, primary infections occur very
early in life [2]. This is partly responsible for greater EBV-
associated HL in developing countries than in developed
countries [2]. Since studies on EBV load in malignancies and
HL from India are limited, the aim of this study was to inves-
tigate the utility of plasma Epstein Barr viral load as a marker
of EBV association in adult-onset HL patients.
Materials and methods
Type of study
This was a prospective study carried out at a tertiary care
cancer center in south India. The study was approved by
the institutional ethics committee and was performed as
per the Helsinki Declaration 2000. A written, informed con-
sent was obtained from all patients enrolled in the study.
Patient selection
The target population included patients with a diagnosis of
HL following a detailed histopathological examination and
immunohistochemistry (IHC). Staging evaluation included a
complete history, thorough physical examination, imaging
(computed tomography [CT] scan of the thorax, abdomen,
and pelvis), and bone marrow aspiration and biopsy. Data
regarding demography, clinical staging, International Prog-
nostic Score (IPS), chemotherapy administered, and clinical
outcome were recorded. Response assessment was done
based on standard criteria [17,18]. Positron emission
tomography-CT scan was not done on any patient as it wasnot available at our center due to the poor affordability of
the patients we cater to.
Sample collection
Peripheral blood samples were collected before initiation of
anticancer chemotherapy in newly diagnosed HL patients
and in healthy voluntary blood donors. In HL patients,
follow-up plasma samples at the end of three courses of
chemotherapy were collected whenever possible. In order
to validate the performance characteristics of the plasma
viral DNA assay, EBV latent membrane protein-1 (LMP1)
IHC was also performed in a subset of cases.
Laboratory protocol
All samples were handled with sterile precautions. Plasma
was separated from all blood samples (pretherapy, post-
therapy, or blood donors) within a few hours of collection
by centrifugation at 1200g for 2 min and stored frozen at
20 C until DNA extraction. All samples were found to be
seronegative for human immunodeficiency virus and hepati-
tis B virus.
Real-time polymerase chain reaction
Nucleic acid was extracted from 250 lL of plasma with a
silica based manual extraction protocol, and eluted with
50 lL elution buffer. The manual method was chosen over
commercial extraction columns as it gave better and more
consistent results (data not shown) [16]. Plasma EBV DNA
in samples was quantified using real-time polymerase chain
reaction (PCR) as per previously published protocol [13].
The standard curve was constructed using EBV DNA of
known concentration diluted 10-fold (a kind gift from
Professor Y.L. Kwong, University Department of Medicine,
Queen Mary Hospital, Pok Fu Lam, Hong Kong). As optimized
and validated in other major studies, EBV DNA load more
than 500 copies/mL was considered as positive [8,14]. In
order to validate the performance characteristics of the
plasma viral DNA assay, in addition to routine IHC for
confirmation of lymphoma diagnosis, EBV LMP1 IHC could
be performed in 25 HL cases.
Results
Over a period of 10 months, 130 histologically confirmed
cases of adult-onset lymphomas were diagnosed of which
33 were HL, while the remaining were nonHodgkin lym-
phomas. Thirty age-matched healthy blood donors (all men)
were included as controls. Of the 33 patients with HL, 27
10 M. Sinha et al.patients received treatment at our center, while four patients
did not opt for treatment and two patients defaulted after the
second chemotherapy cycle and were lost to follow-up.
Of the 33 histologically confirmed, newly diagnosed,
adult-onset HLs, 25 were men and eight were women, with
a mean age of 39.5 ± 16.8 years (range, 18–77 years;
Table 1). The most common lymph nodes involved at pre-
sentation were the cervical lymph nodes. The spleen was
involved in four patients while bulky mediastinal tumor
was found in two patients. None of the patients had bone
marrow involvement as evidenced with bone marrow
biopsy/aspiration. All patients received therapy with dox-
orubicin, bleomycin, vinblastine, and dacarbazine in all
stages of disease as part of the institutional protocol. In
addition, involved field radiation therapy was administered
in seven patients with Stage 1 or 2 HL.
Pretherapy plasma EBV DNA was detectable in 16 of 33
HL patients (48.5%). The viral load of the samples ranged
from 1.0  103 copies/mL to 51.2  103 copies/mL (mean,
18  103 copies/mL; Table 1). Pretherapy EBV DNA was
detected in six of the 16 nodular sclerosis subtype (37.5%)
and six of the 10 mixed cellularity subtype (60%). Of theTable 1 Adult-onset Hodgkin lymphoma patients’ characteristic
Variables
Age (y) Mean (range)
Sex Men:women
Histological subtype Nodular sclero
Mixed cellular
Nodular lymph
Not classifiable
Staging 1
2
3
4
Data not availa
B symptoms Yes
No
Data not availa
IPS 0–2
3–7
Data not availa
LMP1 IHC LMP1 positive
LMP1 negative
Not done
Pretherapy plasma EBV DNA EBV DNA prese
EBV DNA absen
Outcome after therapy Clinical remiss
Partial remissi
Default after 2
No follow-up/t
Data not availa
Note. EBV = Epstein Barr Virus; IHC = immunohistochemistry; IPS = Int
y = year.
a Patients in whom staging, IPS, and outcome could not be determine33 HL cases included in the study, EBV LMP1 IHC could only
be performed in 25, as tissue blocks were inadequate/
unavailable in eight cases. Of these, 14 were LMP1 positive
(56%), 12 of whom had detectable plasma EBV DNA using
PCR. The 11 LMP1 negative cases were also negative for
plasma EBV DNA.
In the eight HL patients in whom follow-up samples were
available, only five patients had detectable pre-therapy
plasma EBV DNA (Table 2). In them, viral load reverted to
negative postchemotherapy and was associated with clinical
remission in four patients and partial remission in one.
Unlike in patients with complete response, the patient with
partial response had a poor IPS of 5 at diagnosis. In the three
follow-up patients without pretherapy plasma EBV DNA,
post-therapy EBV DNA levels remained negative. EBV DNA
was undetectable in plasma samples from all 30 healthy
blood donors.
Discussion
Increased use of Epstein–Barr viral loads in assessing
viral association, in risk stratification, and in assessings.
All patients (n = 33)
39.5 (18–77)
25:8
sis 16
10
ocyte predominant 1
6
4
13
10
1
ble 5a
11
17
ble 5a
20
8
ble 5a
14
11
8
nt 16
t 17
ion 19
on 3
cycles 2
herapy taken 4
ble 5a
ernational Prognostic Score; LMP1 = latent membrane protein-1;
d due to discharge before staging/before therapy could be started.
Table 2 Follow-up cases of adult Hodgkin lymphoma.
Serial
number
Age (y)/sex Type of
lymphoma
Ann arbor
stage
IPS LMP1 IHC Prechemotherapy
viral load (copies/mL)
Postchemotherapy
viral load (copies/mL)
Clinical
outcome
1 20/F HL ns 2B 2 Negative 0 0 CR
2 32/M HL ns 2B 2 Positive 1024 0 CR
3 22/F HL mc 1A 2 Negative 0 0 CR
4 53/M HL unclassified 3A 2 Not done 0 0 CR
5 65/M HL mc 3A 5 Positive 1238 0 PR
6 38/M HL ns 2A 1 Positive 7547 0 CRa
7 21/M HL ns 2A 1 Positive 29,916 0 CR
8 26/M HL ns 2A 1 Positive 30,190 0 CRa
Note. CR = complete remission; F = female; HL = Hodgkin lymphoma; IPS = International Prognostic Score; LMP1 IHC = latent membrane
protein-1 immunohistochemistry; M = male; mc = mixed cellularity; ns = nodular sclerosis; PR = partial remission; y = year.
a Radiation therapy in addition to chemotherapy.
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tive PCR in detecting and monitoring HL [5,7–9,14,19].
The present study highlights the utility of plasma EBV DNA
in determining EBV association in adult onset HL in the
Indian context.
In this study, the mean age of onset of HL was 39.5 years
with a male preponderance. These demographics are con-
cordant with studies on adult HL from India and abroad
[1,3,15]. In this study, 39% of the patients had constitu-
tional ‘‘B” symptoms. In developed countries, ‘‘B” symp-
toms are found in 25–30% of HL, whereas in developing
countries it is found in about 50% of cases [20,21].
Similar to earlier studies from our Institute and abroad,
nodular sclerosis was the most common subtype identified
in this study [8,9,14,22–24]. However, clinico-
epidemiological studies from India show a predisposition
towards mixed cellularity subtype [15,21]. Not all subtypes
of HL harbor EBV to the same degree. Studies have shown
EBV association in 70% of mixed cellularity, 10–40% of
nodular sclerosis, >95% of lymphocyte-depleted, and is
almost always EBV negative in lymphocyte-predominant HL
[19,25]. In the present study, EBV DNA was detectable in
37.5% of nodular sclerosis and 60% of the mixed cellularity
and was negative in the single patient with lymphocyte pre-
dominant subtype.
EBV positivity in HL varies with geographical location;
20–50% in the West, 57–64% in the Far East, and up to
90% in developing countries [2,3,19,25,26]. Using plasma
EBV DNA estimation in adult-onset HL, studies from Aus-
tralia, North American, and Europe found 15–20% EBV asso-
ciation, while a study from Brazil revealed a 43% EBV
association [7,8,14,24]. In this study, plasma EBV DNA was
detectable in 49% of adult HL patients. Based on LMP1
IHC, our study found EBV association in 56% of HL patients.
Similar studies from India (based on either LMP1 IHC or
Epstein–Barr encoding region in situ hybridization) also
revealed a 58–77% EBV association in adult HL [20,22,27].
In our study, the sensitivity of EBV real-time PCR with
respect to LMP1 IHC was 86% while its specificity was
100%. Studies estimate sensitivity of EBV PCR to be 65–
100% [8–10,14]. The inability to detect EBV DNA in all cases
of LMP1-positive HL could be due to the low copy numbersof DNA in these cases [5,19]. Sensitivity of PCR and viral
load depends on patients’ sample, efficiency of DNA extrac-
tion, target gene amplified, and the PCR technique used [5].
In this study, the source of sample was patients’ plasma as it
has been shown to correlate with EBV-associated lym-
phomas more closely than whole blood or PBMCs [5–8].
DNA extraction was performed using a manual, silica-
based protocol as it was found to be more effective than
commercially available extraction columns as has been
noted in other studies [12,28]. EBNA1 was the target gene
amplified in our study as it is detectable uniformly in HL
and is not present in multicopies. This helped determine
viral load unlike multicopy genes like BamH1-W which may
improve sensitivity but may not reflect the true viral load.
Real-time PCR, as used in the present study, has been used
for HL since 1999 and its speed, accuracy, and high through-
put has outdone other quantitative and conventional PCR
methods and is hence widely used for measuring EBV load
[10–12].
Epstein Barr viral load is increasingly being used as a bio-
marker not only to estimate EBV association at diagnosis,
but also for monitoring response to therapy in EBV-
positive lymphomas [7,8,13,14]. Several studies have con-
clusively found therapeutic response to be associated with
decline in viral load [7,14]. Despite our efforts, follow-up
plasma postchemotherapy could be obtained in very few
patients with pretherapy EBV positivity. Reversion of viral
load to undetectable levels in these patients was associated
with response to chemotherapy. Considering the fact that
EBV is almost uniformly present latently in the Indian adult
population, EBV reactivation did not occur in this study. This
is evidenced by the few follow-up patients in whom EBV-
negative status at diagnosis remained negative
postchemotherapy despite dipping white blood cell count
secondary to chemotherapy. Cell-free circulating EBV DNA
has been found to correlate to parameters of disease activ-
ity, such as stage and IPS [7,9]. However, no such correla-
tion was found, probably due to the modest number of
cases in this study.
Considering a high EBV association in adult-onset HL and
also postchemotherapy reversal of plasma viral loads in
remission, viral load estimation maybe a useful tool for
12 M. Sinha et al.detecting EBV association and its variations in this region.
Future studies on larger patient samples with better
follow-up sampling are needed to validate the prognostic
use of the assay in EBV-associated lymphomas.
Conclusion
Our study reveals 49% of newly diagnosed, adult-onset HL
to be EBV-associated based on plasma EBV DNA quantita-
tion. However, EBV LMP1 IHC revealed a 56% EBV association
in a subset of the patients. Sensitivity and specificity of
plasma EBV DNA detection (with respect to LMP1 IHC) was
86% and 100% respectively. Although plasma EBV DNA load
did not correlate with parameters of disease activity, clear-
ance of EBV DNA postchemotherapy correlated well with
remission in all patients sampled. The ease of sampling
and performance of the viral load assay may render it a use-
ful tool for detecting EBV-association and for monitoring
response to therapy in virus-related HL. In the Indian
context, where a high percentage of patients have
EBV-positive HL and may not be able to afford the expensive
positron emission tomography and CT scanning for assessing
therapeutic response to anticancer chemotherapy, the EBV
DNA quantitation assay may, in future, prove to be a valu-
able tool to assess therapeutic response and help decide
adequacy of the number of chemotherapy cycles required.
There is, however, a need for well-designed follow-up stud-
ies to determine the utility of this assay in prognosticating
EBV-positive HL.
Conflicts of interest
The authors declare no conflicts of interest.Acknowledgments
This work was supported by a grant from Rajiv Gandhi
University of Health Sciences, Karnataka, India to M.S. How-
ever the funding agency had no role in study design, collec-
tion, analysis, and interpretation of data, in writing of the
report, and in decision to submit the article for publication.
The authors wish to gratefully acknowledge the generous
gift of quantified EBV DNA by Professor Y.L. Kwong. Our
thanks to Mr. Chandrashekhar, technologist at the
Neuro-oncology Laboratory at National Institute of Mental
Health and Neurosciences (NIMHANS), headed by Dr. Vani
Santosh, for preparation of the tissue microarrays for
LMP1 immunohistochemistry.References
[1] Rickinson A. Epstein–Barr virus. Virus Res 2002;82:109–13.
[2] Hsu JL, Glaser SL. Epstein–Barr virus-associated malignancies:
epidemiologic patterns and etiologic implications. Crit Rev
Oncol Hematol 2000;34:27–53.
[3] Glaser SL, Lin RJ, Stewart SL, Ambinder RF, Jarrett RF,
Brousset P, et al. Epstein–Barr virus associated Hodgkin’s
disease: epidemiologic characteristics in international data.
Int J Cancer 1997;70:375–82.[4] Ga¨rtner B, Preiksaitis JK. EBV viral load detection in clinical
virology. J Clin Virol 2010;48:82–90.
[5] Kimura H, Ito Y, Suzuki R, Nishiyama Y. Measuring Epstein–Barr
virus (EBV) load: the significance and application for each EBV-
associated disease. Rev Med Virol 2008;18:305–19.
[6] Gulley ML, Tang W. Laboratory assays for Epstein Barr related
disease. J Mol Diagn 2008;10:279–92.
[7] Gandhi MK, Lambley E, Burrows J, Dua U, Elliott S, Shaw PJ,
et al. Plasma Epstein–Barr virus (EBV) DNA is a biomarker for
EBV-positive Hodgkin lymphoma. Clin Cancer Res
2006;12:460–4.
[8] Kanakry JA, Li H, Gellert LL, Lemas MV, Hsieh WS, Hong F,
et al. Plasma Epstein–Barr virus DNA predicts outcome in
advanced Hodgkin’s lymphoma: correlative analysis from a
large North American co-operative group trial. Blood
2013;121:3547–53.
[9] Hohaus S, Santangelo R, Giachelia M, Vannata B, Massini G,
Cuccaro A, et al. The viral load of Epstein–Barr virus (EBV) DNA
in peripheral blood predicts for biological and clinical charac-
teristics in Hodgkin lymphoma. Clin Cancer Res
2011;17:2885–92.
[10] Gallagher A, Armstrong AA, MacKenzie J, Shield L, Khan G,
Lake A, et al. Detection of Epstein–Barr virus (EBV) genomes in
the serum of patients with EBV-associated Hodgkin’s disease.
Int J Cancer 1999;84:442–8.
[11] Kimura H, Morita M, Yabuta Y, Kuzushima K, Kato K, Kojima S,
et al. Quantitative analysis of Epstein–Barr virus load by using
a real-time PCR assay. J Clin Microbiol 1999;37:132–6.
[12] Niesters HGM, van Esser J, Fries E, Wolthers KC, Cornelissen J,
Osterhaus AD. Development of a Real-time quantitative assay
for detection of Epstein–Barr virus. J Clin Microbiol
2000;38:712–5.
[13] Au WY, Pang A, Choy C, Chim C, Kwong Y. Quantification of
circulating Epstein–Barr virus (EBV) DNA in the diagnosis and
monitoring of natural killer cell and EBV-positive lymphomas in
immunocompetent patients. Blood 2004;104:243–9.
[14] Spacek M, Hubacek P, Markova J, Zajac M, Vernerova Z,
Kamaradova K, et al. Plasma EBV-DNA monitoring in Epstein–
Barr virus-positive Hodgkin lymphoma patients. Acta Pathol
Microbiol Immunol Scand 2010;119:10–6.
[15] Chakrabarti S, Sarkar S, Goswami BK, Mondal S, Roy A, Das S.
Hodgkin’s and Non-Hodgkin’s Lymphomas in an Indian rural
medical institution: comparative clinicopathologic analysis.
Asian Pac J Cancer Prev 2010;11:1605–8.
[16] Boom R, Sol CJ, Salimans MM, Jansen CL, Wertheim-van Dillem
PM, van der Noordaa J. Rapid and simple method for purifi-
cation of nucleic acids. J Clin Microbiol 1990;28:495–503.
[17] Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L,
Horning SJ, et al. Revised response criteria for malignant
lymphoma. International Harmonization Project on Lym-
phoma. J Clin Oncol 2007;25:579–86.
[18] Hasenclever D, Diehl V. A prognostic score for advanced
Hodgkin’s disease. N Engl J Med 1998;339:1506–14.
[19] Flavell KJ, Murray PG. Hodgkin’s disease and the Epstein–Barr
virus. J Clin Pathol Mol Pathol 2000;53:262–9.
[20] Naresh KN, Johnson J, Srinivas V, Soman CS, Saikia T, Advani
SH, et al. Epstein–Barr virus association in classical Hodgkin’s
disease provides survival advantage to patients and correlates
with higher expression of proliferation markers in Reed–
Sternberg cells. Ann Oncol 2000;11:91–6.
[21] Dinand V, Dawar R, Arya LS, Unni R, Mohanty B, Singh R.
Hodgkin’s lymphoma in Indian children: prevalence and signif-
icance of Epstein–Barr virus detection in Hodgkin’s and Reed–
Sternberg cells. Eur J Cancer 2007;43:161–8.
[22] Rao CR, Franklin J, Lalitha N, Bhatia K, O’Conor G, Magrath I.
Frequency of Epstein Barr Virus (EBV) association and p53
expression in childhood and adult Hodgkin’s Disease in India.
Int J Paediatr Haematol Oncol 2000;6:377–86.
Plasma Epstein Barr Viral Load in Hodgkin Lymphoma 13[23] Sinha M, Rao CR, Shafiulla M, Appaji L, Bs AK, Sumati BG, et al.
Cell free Epstein Barr viral loads in childhood Hodgkin’s
Lymphoma: a pilot study from South India. Pediatr Hematol
Oncol 2013;30:537–43.
[24] Musacchio JG, Carvalho MG, Morais JC, Silva NH, Scheliga A,
Romano S, et al. Detection of free circulating Epstein–Barr
virus DNA in plasma of patients with Hodgkin’s disease. Sao
Paulo Med J 2006;124:154–7.
[25] Thompson MP, Kurzrock R. Epstein–Barr virus and cancer. Clin
Cancer Res 2004;10:803–21.[26] Ambinder RF. Epstein–Barr virus and Hodgkin lymphoma.
Hematol 2007;2007:04–209.
[27] Rajalakshmi T, Payal K, Makhija P, Karuna V. Epstein–Barr
virus in Hodgkin’s lymphoma-Incidence and prognostic impli-
cations. Ind J Med Paediatr Oncol 2006;27:23–6.
[28] Schuurman T, van Breda A, de Boer R, Kooistra-Smid M, Beld M,
Savelkoul P, et al. Reduced PCR sensitivity due to impaired
DNA recovery with the MagNA Pure LC Total Nucleic Acid
Isolation Kit. J Clin Microbiol 2005;43:4616–22.
